NCT06993922View on ClinicalTrials.gov

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
DexmedetomidineAdjuvantBupivacaineScalp BlockPostoperative PainCraniotomy
Interventions
OTHER

Scalp block

Patients will receive a scalp block with bupivacaine alone.

OTHER

Scalp block + Dexmedetomidine

Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.

Trial Locations (1)

11591

RECRUITING

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06993922 - Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy | Biotech Hunter | Biotech Hunter